637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III

Trial in progress Multi center clinical trial to replace BM analysis of cytopenia with a peripheral blood assay

Validation of the international working group IWG 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes HR MDS using a large international randomized Phase 3 clinical trial dataset

Prevalence clinical correlates and clonal inferences of concurrent splicing factor mutations in patients with myeloid neoplasms

A phase I II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes

Efficacy and safety of G CSF in combination with venetoclax and azacitidine VAG in treatment of patients with higher risk Myelodysplastic Syndromes MDS

Phase I study of lower dose CPX 351 combined with venetoclax for patients with higher risk myelodysplastic syndrome or chronic myelomonocytic leukemia after hypomethylating agents failure

Evaluating the impact of stem cell transplantation in myelodysplastic syndrome using machine learning and comparative modeling

Reduced overall survival in TP53 mutated ccus is driven by prior cytotoxic exposure and cytopenia rather than leukemic progression

Artificial intelligence based diagnosis of myelodysplastic syndromes neoplasms using bone marrow

Complex cytogenetics in myeloid malignancies A deconstruction analysis redefining complex karyotypes

Identification of novel predictors of cardiovascular disease risk in MDS patients Results of a prospective observational single centre cohort study

Real world treatment patterns and outcomes of first line luspatercept in patients with myelodysplastic syndromes in the United States

Safety and efficacy of selinexor sequential azacytidine in newly diagnosed patients with myelodysplastic syndromes EB1 or EB2 A single center single arm phase ib II trial

MC210807 Phase 1 clinical trial assessing the safety and efficacy of onvansertib a novel oral PLK1 inhibitor in Relapsed Refractory myeloproliferative chronic myelomonocytic leukemia CMML

A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS A multicenter real‑world cohort study KOTOSG

Non invasive MDS diagnostic algorithm can also identify pre MDS and distinguishes normal controls from MDS pre MDS patients without bone marrow examination

Luspatercept for the treatment of transfusion dependent anemia in patients with myelodysplastic neoplasms with del5q refractory resistant intolerant to prior treatments QOL ONE Phoenix

Azacitidine AZA and venetoclax VEN combination for the treatment of immune mediate inflammatory diseases IMID associated with myeloid neoplasms MN

A multi center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data

RIT1 mutations in myeloid neoplasms

Exposure to agent orange and risk of myelodysplastic syndromes

Azacitidine and luspatercept metronomic therapy for intermediate to high risk myelodysplastic syndrome A prospective single center phase II clinical trial

Not all that glitters is gold A simple clinical score to unmask adverse SF3B1WT MDS RS with low blast count

Insights into clonal and CBC changes at disease evolution among ccus patients